A predictive diagnostic model for refractory diffuse large B-cell lymphoma: a single-center retrospective cohort study

难治性弥漫性大B细胞淋巴瘤的预测诊断模型:一项单中心回顾性队列研究

阅读:1

Abstract

To develop a baseline predictive model for refractory diffuse large B-cell lymphoma (DLBCL) utilizing imaging data including ultrasound findings and PET-CT in conjunction with clinical parameters. We retrospectively analyzed data from 140 patients with newly diagnosed DLBCL treated at Peking University Third Hospital between January 2018 and January 2023. All patients underwent ultrasound, histopathological examinations and PET-CT examinations. After completing 6-8 cycles of standardized chemotherapy, patients were categorized into refractory and non-refractory groups according to the Lugano International Response Assessment Criteria. Univariate analyses were performed using T-tests and Chi-Squared Tests, and independent risk factors for refractory DLBCL were identified through logistic regression. A nomogram predictive model was constructed using the R package "rms," and its predictive performance was subsequently validated. Univariate analysis and logistic regression identified that blurred margins of the affected lymph nodes in ultrasound images (P < 0.001, OR = 18.238) and IPI score(P = 0.051, OR = 3.131) were significant risk factors for disease progression. The predictive nomogram established for refractory diffuse large B-cell lymphoma demonstrated an area under the receiver operating characteristic curve (AUC) of 0.835, with a sensitivity of 85.5% and specificity of 79.5%. Following internal validation, the predictive model exhibited a high degree of alignment between the estimated risk of refractory diffuse large B-cell lymphoma and the actual observed progression events. The prediction model of the R-DLBCL prediction model, amalgamating ultrasonic characterizations and clinical indicators, proves instrumental in identifying high-risk DLBCL groups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。